+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use



The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use



American Heart Journal 150(4): 725-728



Background Assessment of pulmonary vasodilator responsiveness is important in determining the prognosis and management of patients with pulmonary hypertension. Many patients, however, are already on vasodilators at the time of testing. It is unclear if these agents should be temporarily discontinued to improve the sensitivity of testing.Methods We examined the hemodynamic effects of nitric oxide (NO) inhalation in 60 patients with pulmonary arterial hypertension.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012676231

Download citation: RISBibTeXText

PMID: 16209974

DOI: 10.1016/j.ahj.2004.10.012


Related references

Vasodilator response to inhaled nitric oxide is the most powerful predictor of survival in patients with pulmonary hypertension. Circulation 108(17 Supplement): IV-561, October 28, 2003

The pulmonary vasodilator response to inhaled nitric oxide as a function of artery diameter. FASEB Journal 13(4 PART 1): A498, March 12, 1999

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Inhaled nitric oxide a selective vasodilator for the treatment of pulmonary artery hypertension in congenital heart disease. Pediatric Research 31(4 PART 2): 20A, 1992

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2005

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Phosphodiesterase inhibition with dipyridamole augments and prolongs the pulmonary vasodilator response to inhaled nitric oxide in adults with chronic pulmonary hypertension. Circulation 98(17 SUPPL ): I614, Oct 27, 1998

Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 100(18 SUPPL ): I 240, Nov 2, 1999

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110(15): 2253-2259, 2004

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Relationship of baseline hypoxemia to the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatric Research 39(4 PART 2): 344A, 1996

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. American Journal of Respiratory and Critical Care Medicine 151(2 Pt 1): 384-389, 1995

Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respiratory Medicine 98(3): 225-234, 2004

Long term intravenous epoprostenol results in vascular remodeling and enhances vasodilator reserve to inhaled nitric oxide in severe pulmonary artery hypertension. Circulation 104(17 Supplement): II 404, October 23, 2001

A double masked, randomized, placebo controlled, dose-response study of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. Pediatric Research 41(4 PART 2): 144A, 1997